Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 551 - 575 of 8377 in total
Mantle cell lymphoma is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as ibrutinib and acalabrutinib, the prognosis for MCL patients remains poor and those that relapse...
Approved
Matched Description: … to as KTE-X19, uses a method of T cell enrichment that decreases the prevalence of CD19-expressing tumour ... Mantle cell lymphoma is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified ... Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as [ibrutinib] and [acalabrutinib …
Cilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure. It belongs to the angiotensin-converting enzyme inhibitors (ACE inhibitors) class of drugs. It is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat. It is branded as Inhibace in Canada and...
Approved
Matched Description: … None of these varieties are available in the United States. ... Cilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure. ... It belongs to the angiotensin-converting enzyme inhibitors (ACE inhibitors) class of drugs. …
Tapinarof is a novel, first-in-class, small-molecule AhR agonist that is indicated for the treatment of adult psoriasis. It is available as a topical cream to be applied to the affected area once daily.[L41845, A248790] Tapiranof was first discovered as a metabolite (3,5-dihydroxy-4-isopropylstilbene) produced in Photorhabdus luminescens, a gram-negative bacillus that...
Approved
Investigational
Matched Description: … Tapinarof is a novel, first-in-class, small-molecule AhR agonist that is indicated for the treatment of ... [A248790] In 1959, it was noticed that _Heterorhabditis_ with a high amount of 3,5-dihydroxy-4-isopropylstilbene …
Plecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC). It should not be used in children less than six years of age, and should be avoided in patients six years to 18 years of age
Approved
Investigational
Matched Description: … to 18 years of age ... Plecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation ... It should not be used in children less than six years of age, and should be avoided in patients six years …
Gamolenic acid, or gamma-linolenic acid (γ-Linolenic acid) or GLA, is an essential fatty acid (EFA) comprised of 18 carbon atoms with three double bonds that is most commonly found in human milk and other botanical sources . It is an omega-6 polyunsaturated fatty acid (PUFA) also referred to as 18:3n-6;...
Approved
Investigational
Matched Description: … ] and [DB11238] are rich sources of gamolenic acid. ... acid, or gamma-linolenic acid (γ-Linolenic acid) or GLA, is an essential fatty acid (EFA) comprised of ... It is converted to [DB00154], a biosynthetic precursor of monoenoic prostaglandins such as PGE1. …
Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris. It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist. In 2010 a clinical trial has suggested a use for this medication in the prevention of...
Approved
Investigational
Matched Description: … rupture in which the layers of the vessel separate prior to complete failure of the artery wall). ... This study demonstrated decreased incidence of arterial rupture or dissection (a specific type of arterial ... of a rare inherited disease called vascular Ehlers–Danlos syndrome. …
Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a non-ergot dopamine agonist drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement) . It was first approved by the FDA in 1997 . Parkinson's Disease is...
Approved
Investigational
Matched Description: … Parkinson's Disease is one of the most common neurodegenerative disorders and causes a high level of ... Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). ... The prevalence of Parkinson's Disease worldwide has increased from approximately 2.5 million in 1990 …
Iron deficiency is an extremely common condition and is the most frequent cause of anemia worldwide. Iron deficiency results when iron intake, iron stores, and loss of iron from the body do not adequately support production of erythrocytes, also known as red blood cells. Though it is generally considered non...
Approved
Matched Description: … [A190528] Ferric derisomaltose is a form of iron used in the treatment of iron deficiency. ... support production of erythrocytes, also known as red blood cells. ... This drug is a complex of iron (III) hydroxide and derisomaltose. …
Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the...
Approved
Matched Description: … high levels of insulin in a short period of time to mimic the release of endogenous insulin from the ... , with a goal of avoiding any periods of hypoglycemia. ... Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type …
Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.
Approved
Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.[A32038,L12855] Due to its high hydrophilicity and poor absorption profile, prodrug ,fenofibrate, and other conjugated compounds...
Approved
Matched Description: … hydrophilicity and poor absorption profile,[A32038] prodrug ,[fenofibrate], and other conjugated compounds of
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase...
Approved
Investigational
Matched Description: … [A191379, A222393] Broad antiviral activity of remdesivir is suggested by its mechanism of action,[A222398 ... Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease ... 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and …
Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a degree...
Approved
Matched Description: … [label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate ... [A179077] While slightly reduced, possibly due to a degree of cyclooxygenase-2 selectivity (COX-2), nabumetone …
Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA...
Approved
Investigational
Matched Description: … relapsed of refractory acute myeloid leukemia in adults. ... [A248745] Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of ... A248750] Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of
A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure.
Approved
Investigational
Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as...
Approved
Investigational
Matched Description: … , a class of compounds that act upon endogenous cannabinoid receptors of the body [A32584]. ... psychoactive component of cannabis (marijuana). ... Nabilone is a racemate consisting of the (S,S) and the (R,R) isomers. …
Crizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease. Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of India. The genetic mutation associated with this disease leads to the...
Approved
Investigational
Matched Description: … of reducing morbidity and mortality. ... Crizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive ... disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of
Melphalan flufenamide, also known as melflufen or J1, is a prodrug of melphalan.[A230123,L32173] Melphalan flufenamide is more readily uptaken by cells than melphalan, and is cleaved to the active metabolite by aminopeptidases. In vitro models show that melphalan is 10 to hundreds of times more potent than melphalan. The increased...
Approved
Withdrawn
Matched Description: … Melphalan flufenamide, also known as melflufen or J1, is a prodrug of [melphalan]. ... [A230123] _In vitro_ models show that melphalan is 10 to hundreds of times more potent than melphalan ... option for patients with relapsed or refractory multiple myeloma who have attempted at least 4 lines of
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor.[A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced...
Approved
Experimental
Matched Description: … Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid ... [L49101] A biosimilar marketed as Hyrimoz, a high-concentration formulation of adalimumab, is also available …
Sulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and solution. Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common pathogenic dermatophytes, making it an effective treatment for tinea cruris and tinea corporis infections.[L44592,L44597] Sulconazole appears to be effective...
Approved
Matched Description: … Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common ... [L44592,L44597] Sulconazole appears to be effective and well-tolerated in the treatment of superficial …
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … [A243351, A243356, L39411] As the RBD binding site of cilgavimab does not overlap with that of [tixagevimab ... reduce viral load and improve clinical symptoms of infection. ... The FDA and Health Canada advise healthcare providers to inform patients of this risk. …
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … [A243351, A243356, L39411] As the RBD binding site of tixagevimab does not overlap with that of [cilgavimab ... reduce viral load and improve clinical symptoms of infection. ... The FDA and Health Canada advise healthcare providers to inform patients of this risk. …
Bifonazole is an azole antifungal drug.
Approved
Investigational
Vaborbactam is a β-lactamase inhibitor based on a cyclic boronic acid pharmacophore. It has been used in trials investigating the treatment of bacterial infections in subjects with varying degrees of renal insufficiency. In August 2017, a combination antibacterial therapy under the market name Vabomere was approved by the FDA for...
Approved
Investigational
Matched Description: … varying degrees of renal insufficiency. ... Vabomere consists of vaborbactam and [Meropenem] for intravenous administration. ... [A32053] It has been used in trials investigating the treatment of bacterial infections in subjects with …
Vitamin K1, also called phylloquinone or phytonadione, is a fat soluble vitamin.[L33319,L33345] Phylloquinone is a cofactor of the enzyme γ-carboxylase, which modifies and activates precursors to coagulation factors II, VII, IX, and X.[A234264,A234195,A234259] It is indicated in the treatment of coagulation disorders due to faulty formation of coagulation factors II,...
Approved
Investigational
Matched Description: … of coagulation factors II, VII, IX, and X caused by deficiency or interference in the activity of vitamin ... [L33319,L33345] Phylloquinone is a cofactor of the enzyme γ-carboxylase, which modifies and activates ... [A234264,A234195,A234259] It is indicated in the treatment of coagulation disorders due to faulty formation …
Displaying drugs 551 - 575 of 8377 in total